We are delighted to see the excellent article about our #microbiome magic in Drug Target Review!

🔗Read all about it here: drugtargetreview.com/article/112145…

#biotech #lifesciences

⬇️Microbiotica: transforming medicine with microbiome magic

Microbiotica's VP Pre-Clinical Development Adam Wilkinson and VP Clinical Development Claire Birrell are presenting a poster about MB310, our Live Bacterial Therapeutic ( #LBT ) for the treatment of ulcerative colitis, at the #IBDInnovate conference in New York City on April 26.

Pleased to collaborate with MSD to conduct a phase 1b trial to evaluate the safety and clinical activity of MB097 and KEYTRUDA® combination therapy in #melanoma patients #Microbiome #ClinicalTrial Read more here: microbiotica.com/microbiotica-a…

Microbiotica's SVP Research, Mat Robinson, is attending #AACR2023 Annual Meeting in Orlando, FL from Apr 14-19. The global event for cancer researchers and professionals to share cutting-edge advancements in cancer science and medicine.
#CancerResearch #Microbiome

Don't miss our Director of Cell Biology, Ghaith Bakdash, discussing 'Clinic-First Design Of A Live Bacterial Therapeutic (MB310) For #UlcerativeColitis ' and joining a panel on 'Utilising The Microbiome For Autoimmune & Cancer Care' at #Immuno2023 in London on March 28.
#LBT

Our CEO Tim Sharpington is presenting at the Microbiome #innovation showcase during the UK Microbiome One Health Conference in Glasgow on March 24th at 9:55 am!

Join us to learn and discuss everything about the #microbiome #OneHealth .

Discover our groundbreaking work in microbiome-based therapeutics and biomarkers for high medical need areas. Check out the new case study from Wellcome Sanger Institute here: bit.ly/3liATfp

#Microbiome #Genomics #Therapeutics #LBT

Microbiotica’s CEO, Tim Sharpington, will be part of a panel discussion at the 7th #Microbiome Movement conference in London, 1 February at 4:30 PM.

Tim will be exploring how Microbiotica closed a £50M Series B financing round in March 2022.

See you there!

#Microbiome

With 2022 coming to an end, we look forward to advancing our understanding of the role of the #microbiome and building our pipeline.
Read about the impact of the microbiome on #cancer therapy by Mike Romanos and Matthew Robinson in Mednous: lnkd.in/efECR5u2
#LBP

Our VP Preclinical Development Adam Wilkinson will discuss #microbiome -based #therapies as a new modality and the potential of our microbiome #platform at the 19th Annual #bioProcessUK in #Edinburgh . Join his talk at 11:30am Nov 16.
#BIA #BioPharma

bioprocessuk.org

We’re looking forward to the 7th Microbiome Connect USA, 16-17 Nov, with talks covering #biotech , #drugdevelopment , #microbiome and beyond, bringing together #pharma , #investors and industry players to share knowledge, collaborate and address challenges. kisacoresearch.com/events/microbi…

Our new article on unlocking the #microbiome as a multi-therapeutic modality is live on Biopharma Dealmakers.

Read the full article to explore our lead program and its potential in microbiome-based #therapies : nature.com/articles/d4374…

#Partnering #Cancer

Microbiotica's COO Tim Sharpington and CBO Matthew Roe will be attending this year's BIO-Europe in Leipzig, Germany, 24-26 October.

We are excited to return to the industry’s largest gathering of #biopharma professionals in Europe.

See you there!

#BIOEurope #Microbiome

Watch Ghaith Bakdash, Director Cell Biology discuss our work on #microbiome signatures and the newly developed bacterial consortium, highlighting applications of MB097 as potential #therapeutic for #cancer in this interview with MicrobiomePost
microbiomepost.com/how-microbioti…
#LBT

Microbiotica’s Mat Robinson, VP Translational Biology, will be presenting “Precision #Microbiome Profiling Enables Discovery Of A Clinically-Defined Consortium Of Bacteria With Potent Anti-Tumour Activity” at Immuno UK on 29 September at 11:10 AM: oxfordglobal.co.uk/immuno-series-…

Today we join cancer researchers around the world to celebrate #WorldCancerResearchDay !

We are proud to be part of the work being done in the field of #Cancer Research and thank all our dedicated scientists who are contributing to our research.

#Cancer #Microbiome #LBT

Listen to Microbiotica’s co-founder and CSO Trevor Lawley at the 22nd Cambridge Immunology Forum discussing ‘Cancer at the interface of #immunity , #metabolism and #microbiota ’ at Queen’s College, Cambridge University on 23 September.

Find out more here: med.cam.ac.uk/cif2022/

We are honoured to have been shortlisted in the category “Private Financing Deal of the Year” for @Pharma_Intell #ScripAwards .

Thanks to all our investors Tencent 腾讯 #FlerieInvest British Patient Capital Seventure Partners Cambridge Innovation Capital IP Group - visionary ventures

#Awards #Biotech